[The Crohn Disease Study Group].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D003672:Defecation; D005260:Female; D006801:Humans; D007082:Ileum / Q000000981:diagnostic imaging / Q000473:pathology; D007962:Leukocytes / Q000166:cytology / Q000276:immunology / Q000502:physiology; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009113:Muramidase / Q000378:metabolism; D011859:Radiography; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012643:Selenium / Q000378:metabolism; D012460:Sulfasalazine / Q000627:therapeutic use; D013656:Taurocholic Acid / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D011868:Radioisotopes; D000515:alpha 1-Antitrypsin; D012460:Sulfasalazine; D013656:Taurocholic Acid; D009113:Muramidase; D012643:Selenium
Arbeitsgruppe "Morbus Crohn".